Hayden Michael R 4

What Happened Hayden Michael R, a director of AbCellera Biologics Inc., was granted derivative securities covering 111,701 shares on 2026-06-11. The Form 4 lists the acquisition price as $0.00 (no cash paid reported). The transaction is recorded as a grant/award (transaction code A) rather than an open-market buy or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (timely).
• Award: derivative securities covering 111,701 shares; acquisition price shown as $0.00.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The shares subject to the option vest and become exercisable at the 2027 Annual General Meeting, subject to the reporting person's continuous service.
• Transaction code: A (grant/award of a derivative security).

Context This was an award of a derivative security (appears to be an option-like grant) that vests in the future—not an immediate purchase or sale. Such grants are typically compensation or retention tools and may dilute common shares if exercised later; they do not necessarily indicate the insider is buying or selling stock for personal market-directional reasons.